Novavax Overview
- Year Founded
-
1987

- Status
-
Public
- Employees
-
1,992

- Stock Symbol
-
NVAX

- Investments
-
3
- Share Price
-
$8.19
- (As of Friday Closing)
Novavax General Information
Description
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. Novavax works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The Company manages its business as one operating segment, the development and commercialization of vaccines. The company generates maximum revenue from Europe.
Contact Information
Website
global.novavax.comCorporate Office
- 21 Firstfield Road
- Gaithersburg, MD 20878
- United States
Corporate Office
- 21 Firstfield Road
- Gaithersburg, MD 20878
- United States
Novavax Timeline
Novavax Stock Performance
As of 14-Feb-2025, Novavax’s stock price is $8.19. Its current market cap is $1.31B with 160M shares.
(As of Friday Closing)
Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
---|---|---|---|---|---|---|
$8.19 | $8.18 | $3.81 - $23.86 | $1.31B | 160M | 4.03M | -$2.18 |
Novavax Financials Summary
As of 30-Sep-2024, Novavax has a trailing 12-month revenue of $847M.
In Thousands, USD |
TTM 30-Sep-2024 | FY 2023 31-Dec-2023 | FY 2022 31-Dec-2022 | FY 2021 31-Dec-2021 |
---|---|---|---|---|
EV | 1,205,634 | 141,200 | 41,377 | 9,307,338 |
Revenue | 847,250 | 556,382 | 1,598,951 | 197,581 |
EBITDA | (216,355) | (487,390) | (604,713) | (1,680,748) |
Net Income | (284,858) | (545,062) | (657,939) | (1,743,751) |
Total Assets | 1,712,483 | 1,797,490 | 2,258,679 | 2,576,753 |
Total Debt | 233,308 | 229,081 | 549,781 | 453,991 |
Novavax Valuation & Funding
Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
---|
Novavax Comparisons
Industry
Financing
Details
Novavax Competitors (51)
One of Novavax’s 51 competitors is Dynavax Technologies, a Formerly VC-backed company based in Emeryville, CA.
Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
---|---|---|---|---|---|---|
Dynavax Technologies | Formerly VC-backed | Emeryville, CA | ||||
Moderna | Formerly VC-backed | Cambridge, MA | ||||
CureVac | Formerly VC-backed | Tubingen, Germany | ||||
Valneva | Formerly VC-backed | Saint-Herblain, France | ||||
Cytodyn | Formerly Angel backed | Vancouver, WA |
Novavax Patents
Novavax Recent Patent Activity
Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
---|---|---|---|---|---|
US-20240374712-A1 | Sars-cov-2 vaccine compositions | Pending | 24-Apr-2023 | ||
US-20240325523-A1 | Coronavirus and influenza compositions and methods for using them | Pending | 03-Apr-2023 | ||
US-20240076320-A1 | Downstream process for purification of viral proteins with hydrophobic membrane domain for use in vaccine compositions | Pending | 01-Sep-2022 | ||
AU-2023315949-A1 | Pseudovirus based neutralization assay for evaluating vaccine immunogenicity | Pending | 26-Jul-2022 | ||
AU-2023314769-A1 | Ace2 inhibition assay for evaluation of vaccine immunogenicity | Pending | 26-Jul-2022 |
Novavax Signals
Novavax Investments & Acquisitions (3)
Novavax’s most recent deal was a Merger/Acquisition with Novavax CZ for . The deal was made on 27-May-2020.
Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
---|---|---|---|---|---|
Novavax CZ | 27-May-2020 | Merger/Acquisition | Biotechnology | ||
Novavax (Maryland) | 22-Aug-2013 | Merger/Acquisition | Pharmaceuticals | ||
CPL Biologicals | 01-Jan-2009 | Joint Venture | Biotechnology |
Novavax ESG
Risk Overview
Risk Rating
Updated March, 19, 2024
27.15 | Med Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 15,120
Rank
Percentile

Pharmaceuticals
Industry
of 853
Rank
Percentile

Biotechnology
Subindustry
of 368
Rank
Percentile

Novavax Exits (1)
Novavax’s most recent exit was on 27-May-2020 from Novavax CZ. The exit was categorized as .
Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
---|---|---|---|---|---|
Novavax CZ | 27-May-2020 | Completed |
|
Affiliates
Subsidiaries (1)
Name | Industry | Location | Year Founded |
---|---|---|---|
Novavax (150,000-Square Foot Manufacturing Site in Bohumil, Czech Republic) | Bohumil, Czech Republic |
Novavax FAQs
-
When was Novavax founded?
Novavax was founded in 1987.
-
Where is Novavax headquartered?
Novavax is headquartered in Gaithersburg, MD.
-
What is the size of Novavax?
Novavax has 1,992 total employees.
-
What industry is Novavax in?
Novavax’s primary industry is Biotechnology.
-
Is Novavax a private or public company?
Novavax is a Public company.
-
What is Novavax’s stock symbol?
The ticker symbol for Novavax is NVAX.
-
What is the current stock price of Novavax?
As of 14-Feb-2025 the stock price of Novavax is $8.19.
-
What is the current market cap of Novavax?
The current market capitalization of Novavax is $1.31B.
-
What is Novavax’s current revenue?
The trailing twelve month revenue for Novavax is $847M.
-
Who are Novavax’s competitors?
Dynavax Technologies, Moderna, CureVac, Valneva, and Cytodyn are some of the 51 competitors of Novavax.
-
What is Novavax’s annual earnings per share (EPS)?
Novavax’s EPS for 12 months was -$2.18.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »